N4 Pharma的库存上升了4.7%,因为它在炎症肠病方面发展了基因传播技术。 N4 Pharma's stock climbs 4.7% as it advances its gene delivery technology for inflammatory bowel disease.

N4 Pharma是一家开发先进疗法基因传送系统的生物技术公司,其库存在星期三增长了4.7%,达到0.45英镑(0.01美元)。 N4 Pharma, a biotech firm developing a gene delivery system for advanced therapies, saw its stock rise 4.7% on Wednesday, reaching GBX 0.45 ($0.01). 该公司正在扩大其临床前期数据,并致力于人类临床试验,以支持许可交易。 The company is expanding its preclinical data and working towards human clinical trials to support licensing deals. 其牵头项目N4 101是治疗炎性肠道疾病的口服抗炎药,显示了其技术的潜力。 Its lead project, N4 101, is an oral anti-inflammatory for inflammatory bowel disease, demonstrating the potential of its technology.